Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273936 · ClinicalTrials.gov registry record · Phase 1
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00273936 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 72 participants.
The verdict
NCT00273936, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
Interventions
- DRUG AVN-944 capsules for oral administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00273936
The ClinicalTrials.gov registry entry for NCT00273936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVN-944 capsules for oral administration is the first listed.
NCT00273936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00273936 about?
NCT00273936 is a clinical study titled "Trial of AVN-944 in Patients With Advanced Hematologic Malignancies". The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
What is the current status of trial NCT00273936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00273936?
The interventions under investigation include: AVN-944 capsules for oral administration (DRUG).
Who is sponsoring clinical trial NCT00273936?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.